Breaking: Exane BNP Paribas Reconfirms GBX 5700 Target Price On Shire (LON:SHP) Shares, Reconfirms Their Original Neutral Rating

Share

Shire (LON:SHP) Rating Reaffirmed

They currently have a GBX 5700 target on Shire (LON:SHP). The target price by Exane BNP Paribas would suggest a potential upside of 26.22% from the company’s last stock close. This has been revealed to clients and investors in a note on Tuesday morning.

From a total of 10 analysts covering Shire PLC (LON:SHP) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 65% of the ratings are positive. The highest target price is GBX 96.71 while the lowest target price is GBX 81.77. The mean of all analyst targets is GBX 89.63 with a 19.96% above today’s (GBX 4491) stock price. Shire PLC was the topic of 82 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. Bernstein maintained shares on December 7 with “Outperform” rating. Credit Suisse maintained shares with “Neutral” rating and GBX 5400 target share price in a report from a November 4. J.P. Morgan maintained SHP stock in a recent report from December 4 with “Overweight” rating. Barclays Capital maintained the rating on November 3. Barclays Capital has a “Overweight” rating and a GBX 5700 price target on shares. Finally, Berenberg maintained the stock with “Buy” rating in a report issued on a November 16.

Approximately 170,964 shares of stock traded hands. Shire PLC (LON:SHP) has declined 14.11% since May 11, 2015 and is downtrending. It has underperformed by 13.52% the S&P500.

Breaking: Exane BNP Paribas Reconfirms GBX 5700 Target Price On Shire (LON:SHP) Shares, Reconfirms Their Original Neutral Rating

Shire plc is a biopharmaceutical company. The company has a market cap of 26.60 billion GBP. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 13.21 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.

COMMENTS: